APVO
Price
$6.42
Change
-$0.34 (-5.03%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
6.68M
Intraday BUY SELL Signals
KROS
Price
$18.03
Change
-$0.44 (-2.38%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
562.71M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APVO vs KROS

Header iconAPVO vs KROS Comparison
Open Charts APVO vs KROSBanner chart's image
Aptevo Therapeutics
Price$6.42
Change-$0.34 (-5.03%)
Volume$594
Capitalization6.68M
Keros Therapeutics
Price$18.03
Change-$0.44 (-2.38%)
Volume$19.75K
Capitalization562.71M
APVO vs KROS Comparison Chart in %
View a ticker or compare two or three
VS
APVO vs. KROS commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APVO is a Hold and KROS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (APVO: $6.76 vs. KROS: $18.47)
Brand notoriety: APVO and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APVO: 43% vs. KROS: 48%
Market capitalization -- APVO: $6.68M vs. KROS: $562.71M
APVO [@Biotechnology] is valued at $6.68M. KROS’s [@Biotechnology] market capitalization is $562.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APVO’s FA Score shows that 1 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • APVO’s FA Score: 1 green, 4 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, both APVO and KROS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APVO’s TA Score shows that 5 TA indicator(s) are bullish while KROS’s TA Score has 5 bullish TA indicator(s).

  • APVO’s TA Score: 5 bullish, 3 bearish.
  • KROS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, APVO is a better buy in the short-term than KROS.

Price Growth

APVO (@Biotechnology) experienced а -18.16% price change this week, while KROS (@Biotechnology) price change was +0.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

KROS is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KROS($563M) has a higher market cap than APVO($6.68M). KROS has higher P/E ratio than APVO: KROS (11.84) vs APVO (0.00). KROS YTD gains are higher at: -9.283 vs. APVO (-28.314). KROS has higher annual earnings (EBITDA): 68.8M vs. APVO (-26.47M). KROS has more cash in the bank: 693M vs. APVO (3.23M). APVO has less debt than KROS: APVO (3.99M) vs KROS (17.4M). KROS has higher revenues than APVO: KROS (247M) vs APVO (0).
APVOKROSAPVO / KROS
Capitalization6.68M563M1%
EBITDA-26.47M68.8M-38%
Gain YTD-28.314-9.283305%
P/E Ratio0.0011.840%
Revenue0247M-
Total Cash3.23M693M0%
Total Debt3.99M17.4M23%
FUNDAMENTALS RATINGS
APVO vs KROS: Fundamental Ratings
APVO
KROS
OUTLOOK RATING
1..100
9165
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10069
PRICE GROWTH RATING
1..100
9744
P/E GROWTH RATING
1..100
6299
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APVO's Valuation (10) in the Biotechnology industry is somewhat better than the same rating for KROS (59) in the null industry. This means that APVO’s stock grew somewhat faster than KROS’s over the last 12 months.

APVO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KROS (100) in the null industry. This means that APVO’s stock grew similarly to KROS’s over the last 12 months.

KROS's SMR Rating (69) in the null industry is in the same range as APVO (100) in the Biotechnology industry. This means that KROS’s stock grew similarly to APVO’s over the last 12 months.

KROS's Price Growth Rating (44) in the null industry is somewhat better than the same rating for APVO (97) in the Biotechnology industry. This means that KROS’s stock grew somewhat faster than APVO’s over the last 12 months.

APVO's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for KROS (99) in the null industry. This means that APVO’s stock grew somewhat faster than KROS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APVOKROS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 8 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APVO
Daily Signal:
Gain/Loss:
KROS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALB170.645.71
+3.46%
Albemarle Corp
PLUG2.130.05
+2.40%
Plug Power
MGNX1.75N/A
N/A
MacroGenics
ADSE10.76-0.22
-2.00%
Ads-Tec Energy PLC
BGLC2.65-0.17
-6.19%
Bionexus Gene Lab Corp

APVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, APVO has been loosely correlated with GOSS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if APVO jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APVO
1D Price
Change %
APVO100%
-10.34%
GOSS - APVO
42%
Loosely correlated
+7.66%
ENLV - APVO
39%
Loosely correlated
+4.81%
KROS - APVO
37%
Loosely correlated
+0.38%
AXON - APVO
33%
Loosely correlated
-1.89%
SRRK - APVO
28%
Poorly correlated
+2.87%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.38%
INO - KROS
53%
Loosely correlated
-0.59%
AXON - KROS
43%
Loosely correlated
-1.89%
CLDX - KROS
41%
Loosely correlated
+2.07%
ALT - KROS
39%
Loosely correlated
-1.44%
SPHDF - KROS
38%
Loosely correlated
N/A
More